322. Infliximab for Vascular Involvement in Behçet's Synome

Background/ Objectives: Vascular involvement is an important cause of morbidity and mortality in patients with Behçet’s synome (BS). TNF inhibitors have been beneficial for the management of mucocutaneous, eye and gastrointestinal involvement of BS. Data on their efficacy in patients with vascular involvement is scarce. We aimed to survey the efficacy and safety of infliximab (IFX) in BS patients with vascular involvement followed in a dedicated tertiary center. Methods: We reviewed the charts of all BS patients who used IFX for vascular involvement between 2004 and June 2021. A standard form was used for extracting data on demographic and clinical features, type of vascular involvement, concomitant immunosuppressives, duration of IFX use, relapses, adverse events and outcome. The primary endpoint for patients with any vascular involvement was remission defined as lack of new clinical sympto/findings associated with vascular lesion, lack of worsening of the primary vascular lesion, lack of a new vascular lesion on imaging, and CRP